Discover
CNTX
Context Therapeutics Inc.
0.61
2 x 0.43
2 x 0.74
bid
ask
+
0.05
9.82%
2 @ 04:00 PM
0.59 -0.02 (3.45%)
| Ytd | -58.62% | |
| 1y | -3.14% |
0.56
day range
0.63
0.55
52 week range
3.62
| Open | 0.57 | Prev Close | 0.55 | Low | 0.56 | High | 0.63 | Mkt Cap | 55.89M |
| Vol | 4.30M | Avg Vol | 1.85M | EPS | -0.42 | P/E | N/A | Forward P/E | -3.38 |
| Beta | 2.25 | Short Ratio | 2.79 | Inst. Own | 76.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 1.87 | 200-d Avg | 1.77 | 1yr Est | 7.70 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-06 | 2024-09 | -0.11 | -0.22 | -0.11 | -100.00% |
| 2024-08-07 | 2024-06 | -0.08 | N/A | N/A | N/A |
| 2024-08-07 | 2024-06 | -0.08 | -0.04 | 0.04 | 50.00% |
| 2024-05-08 | 2024-03 | -0.38 | -0.23 | 0.15 | 39.47% |
| 2024-05-08 | 2024-03 | -0.38 | N/A | N/A | N/A |
| 2024-03-21 | 2023-12 | -0.35 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-25 | D. Boral Capital | Upgrade | Buy | |
| 2024-09-23 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-16 | Piper Sandler | Upgrade | Overweight | |
| 2024-05-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-02-20 | LEHR MARTIN A | Chief Executive Officer | 979.89K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Deep Track Capital, Lp | 7.42M | 7.27M | 9.89% |
| 2024-09-29 | Nextech Invest Ag | 7.42M | 7.27M | 9.89% |
| 2024-09-29 | Avidity Partners Management, LP | 7.42M | 7.27M | 9.89% |
| 2024-09-29 | Great Point Partners LLC | 6.93M | 6.80M | 9.25% |
| 2024-09-29 | Blue Owl Capital Holdings LP | 5.41M | 5.30M | 7.22% |
| 2024-09-29 | Vanguard Group Inc | 3.74M | 3.67M | 4.99% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 3.12M | 3.06M | 4.17% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 554.82K | 543.73K | 0.74% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 295.08K | 289.18K | 0.39% |
| 2024-10-30 | Fidelity Total Market Index Fund | 99.06K | 97.08K | 0.13% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 69.67K | 68.27K | 0.09% |
| 2024-09-29 | Vanguard Institutional Index-Inst Total Stock Market Ind | 53.13K | 52.06K | 0.07% |